Dodd M E, Abbott J, Maddison J, Moorcroft A J, Webb A K
Bradbury Cystic Fibrosis Unit, Wythenshawe Hospital, Manchester, UK.
Thorax. 1997 Jul;52(7):656-8. doi: 10.1136/thx.52.7.656.
Inhalation of hypertonic nebulised colistin causes chest tightness and is a reason for discontinuing the treatment. This study examines the relationship of chest tightness and change in lung function in response to the inhalation of a range of tonicities of nebulised colistin and their influence on patients' preference.
Twenty seven adult patients with cystic fibrosis and a mean forced expiratory volume in one second (FEV1) of 54% predicted (range 24-98) were studied. They inhaled a nebulised solution of hypertonic, isotonic, and hypotonic colistin over three consecutive days in random order in a double blind fashion. Measurements of chest tightness, using a visual analogue scale (VAS), and FEV1 were recorded before and 0, 15, 30, 60, and 90 minutes following inhalation. The solution preferred by each patient was determined at the end of the three days.
All tonicities caused a significant fall in FEV1 % predicted and an increase in chest tightness, with no differences between the solutions. However, the mean (SE) time to the maximum fall in FEV1 % predicted was significantly different between the solutions (hypertonic 7.8 (2.1) min, isotonic 19.2 (5.5) min, and hypotonic 34.2 (5.9) min) with a mean difference (95% CI) between hypotonic and hypertonic solutions of 28.04 (14.6 to 41.5) min, between isotonic and hypertonic solutions of 12.0 (-0.1 to 24.1) min, and between hypotonic and isotonic solutions of 15.6 (1.8 to 29.4) min. Positive correlations existed for the maximum fall in FEV1 % predicted between the hypertonic and isotonic solutions (r = 0.62, p < 0.001) and between the hypotonic and isotonic solutions (r = 0.64, p < 0.001). There was no correlation between the objective and subjective measurements for any solution. The patients' preference varied.
All tonicities of colistin caused equal symptoms of chest tightness and reduction in pulmonary function. It is recommended that the patient is challenged with nebulised colistin before prescription of the drug and that the challenge is preceded by an inhaled bronchodilator. Most of the patients preferred the isotonic or hypotonic solutions. The isotonic solution reflects a fall in FEV1 representative of all the solutions. The fall in FEV1 to the hypotonic solution occurred over a longer period and may be better tolerated by some patients.
吸入高渗雾化多黏菌素会导致胸闷,这是中断治疗的一个原因。本研究探讨了吸入不同张力的雾化多黏菌素后胸闷与肺功能变化之间的关系及其对患者偏好的影响。
对27例成年囊性纤维化患者进行研究,其一秒用力呼气容积(FEV1)平均为预测值的54%(范围24% - 98%)。他们以双盲方式,随机顺序连续三天吸入高渗、等渗和低渗多黏菌素雾化溶液。在吸入前以及吸入后0、15、30、60和90分钟记录使用视觉模拟量表(VAS)测量的胸闷情况和FEV1。在三天结束时确定每位患者偏好的溶液。
所有张力的溶液均导致预测FEV1%显著下降和胸闷增加,各溶液之间无差异。然而,溶液之间预测FEV1%最大下降的平均(标准误)时间显著不同(高渗7.8(2.1)分钟,等渗19.2(5.5)分钟,低渗34.2(5.9)分钟),低渗与高渗溶液之间的平均差异(95%可信区间)为28.04(14.6至41.5)分钟,等渗与高渗溶液之间为12.0( - 0.1至24.1)分钟,低渗与等渗溶液之间为15.6(1.8至29.4)分钟。高渗与等渗溶液之间以及低渗与等渗溶液之间预测FEV1%最大下降存在正相关(r = 0.62,p < 0.001;r = 0.64,p < 0.001)。任何溶液的客观测量与主观测量之间均无相关性。患者的偏好各不相同。
所有张力的多黏菌素引起的胸闷症状和肺功能降低程度相同。建议在开具该药物处方前让患者吸入雾化多黏菌素进行激发试验,且激发试验前先吸入支气管扩张剂。大多数患者更喜欢等渗或低渗溶液。等渗溶液反映的FEV1下降代表了所有溶液。低渗溶液导致的FEV1下降持续时间更长,可能某些患者耐受性更好。